P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
Chiara Rusconi,
Benedetta Puccini,
Carlo Visco,
Francesca Ricci,
Alessandro Re,
Vittorio R. Zilioli,
Caterina Zerbi,
Stefan Hohaus,
Federico Mazzon,
Manuel Ciceri,
Anna Guidetti,
Vincenzo Marasco,
Luigi Rigacci
Affiliations
Chiara Rusconi
1 Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
Benedetta Puccini
2 SOD Hematology, AOU Careggi, Firenze, Italy
Carlo Visco
3 Department of Medicine, Section of Hematology, University of Verona, Verona, Italy
Francesca Ricci
4 Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy
Alessandro Re
5 Hematology, ASST Spedali Civili di Brescia, Brescia, Italy
Vittorio R. Zilioli
6 Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
Caterina Zerbi
7 Department of Molecular Medicine, University of Pavia and Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Stefan Hohaus
8 Hematology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
Federico Mazzon
9 University of Milan, Milano, Italy
Manuel Ciceri
2 SOD Hematology, AOU Careggi, Firenze, Italy
Anna Guidetti
1 Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
Vincenzo Marasco
1 Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
Luigi Rigacci
10 UOC Hematology and Stem Cell Transplantation, AO San Camillo Forlanini, Roma, Italy
